National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

Statutory Rules 1983 No. 281

___________

 

National Health (Pharmaceutical Benefits) Regulations2 (Amendment)

WHEREAS it is provided by sub-section 101 (4) of the National Health Act 1953 that a drug or medicinal preparation that was not a pharmaceutical benefit under that Act immediately before the commencement of that sub-section shall not be prescribed as a pharmaceutical benefit in accordance with section 85 of that Act unless the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that it be so prescribed:

AND WHEREAS the Pharmaceutical Benefits Advisory Committee has recommended to the Minister that each of the following drugs or medicinal preparations be prescribed as a pharmaceutical benefit under section 85 of that Act, namely—

(a) Captopril;

(b) Carindacillin Sodium; and

(c) “MAXAMAID XP”:

AND WHEREAS it is desirable, amongst other things, to prescribe each of those drugs or medicinal preparations as a pharmaceutical benefit under that section:

NOW THEREFORE I, the Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, hereby make the following Regulations under the National Health Act 1953.

Dated 25 March 1983.

N. M. STEPHEN

Governor-General

By His Excellency’s Command,

(Sgd) Neal Blewett

Minister of State for Health

_________

____________________________________________________________________________________

S.R. 45/83 Cat. No.  Recommended retail price 40c 10/11.3.1983

Commencement

1.These Regulations shall come into operation on 1 April 1983.

Schedule 1

2.Schedule 1 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 1.

Schedule 2

3.Schedule 2 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 2.

Schedule 3

4.Schedule 3 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 3.

Schedule 5

5.Schedule 5 to the National Health (Pharmaceutical Benefits) Regulations is amended as set out in Schedule 4.

_________

 

SCHEDULE 1 Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 103

2. After item 173 insert the following items:

“173a Cephaloridine

“173b Cephtiloridine Injection”.

3. After item 180 insert the following item:

“180a Chloramphenicol Ear Drops”.

4. After item 200 insert the following item:

“200a Chlorotrianisene Tablets”.

5. After item 204 insert the following item:

“204a Chlorpheniramine Maleate”.

6. Omit item 404.

7. Omit item 405.

8. Omit item 406.

9. After item 534 insert the following item:

“534a Isoprenaline Hydrochloride Injection”.

___________

SCHEDULE 2 Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 39.
2. Omit item 56.
3. After item 113 insert the following item:
“113a Flucloxacillin Sodium, B.P.	Purified Water B.P., with Flucloxacillin Sodium, B.P.”.
4. Omit item 160.
5. After item 163 insert the following item:
“163a ‘MAXAMAID XP’	—”.
6. Omit item 244.

___________

 

SCHEDULE 3 Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 38.

2. Omit item 53, substitute the following items:

“53 Camphor Compound Linctus, A.P.F.

“53a Captopril”.

3. Omit item 54, substitute the following items:

“54 Carbachol, B.P. 1973

“54a Carindacillin Sodium”.

4. Omit item 129, substitute the following item:

“129 Influenza Vaccine-Sub Unit

Type (Chemically Treated)”.

5. Omit item 159.

6. After item 161 insert the following item:

“161a ‘MAXAMAID XP’”

7. Omit item 223.

___________

SCHEDULE 4 Regulation 5

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH (PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 2 insert the following item:

“2a ‘ALBUMAID XP’

Phenylketonuria”.

2. After item 4 insert the following item:

“4a ‘AMINOGRAN FOOD

SUPPLEMENT’

Phenylketonuria”.

3. Omit item 6.

4. Omit item 14, substitute the following item:

“14 (1) Bisacodyl Suppositories, B.P.

Any disease or condition in a paraplegic or quadraplegic patient

(2) Bisacodyl Tablets, B.P.

For use by patients who are receiving long-term intensive nursing care in hospitals or nursing homes

For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved”.

5. Omit items 16 and 17, substitute the following item:

“16 Bromocriptine Mesylate

With the written authority of the Permanent Head—

Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate

Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution”.

6. After item 24a insert the following item:

“24b Captopril

With the written authority of the Permanent Head—

For the continuing treatment of severe refractory hypertensive disease where treatment with captopril was initiated in a hospital”.

7. After item 26 insert the following item:

“26a Carindacillin Sodium

With the written authority of the Permanent Head—

Infections where positive bacteriological evidence confirms that carindacillin or carbenicillin is the most appropriate therapeutic agent”.

8. Omit item 28.

9. Omit item 39.

10. Omit item 45.

11. Omit item 47.

12. Omit item 49.

13. After item 74 insert the following item:

“74a (1) Flucloxacillin Capsules, B.P.

With the written authority of the Permanent Head—

(2) Flucloxacillin Sodium, B.P.,

with Purified Water, B.P.

Infections due to the presence of penicillin-resistant staphylococci

Osteomyelitis”.

14. After item 98 insert the following item:

“98a ‘LOFENALAC’

Phenylketonuria”.

SCHEDULE 4—continued

15.	Omit item 99, substitute the following item:
“99 ‘MAXAMAID XP’	Phenylketonuria”.
16.	Omit item 124.
17.	After item 144 insert the following item:
“144a (1) ‘PK AID I’	Phenylketonuria”.
(2) ‘PK AID II’
18.	Omit item 150, substitute the following item:
“150 Prednisolone Acetate Injection	Local intra-articular or peri-articular infiltration”.
19.	Omit item 160.
20.	Omit item 178.
21.	Omit item 179, substitute the following item:
“179 Thiopropazate Hydrochloride Tablets, B.P.	Chorea”.

____________________________________________________________________________________

NOTES

1. Notified in the Commonwealth of Australia Gazette on 31 March 1983.

2. Statutory Rules 1960 No. 17 as amended by 1960 Nos. 90 and 102; 1961 Nos. 59 and 137; 1962 Nos. 34, 101 and 114; 1963 Nos. 34, 69 and 107; 1964 Nos. 12, 57 and 135; 1965 Nos. 51, 151 and 152; 1966 Nos. 80 and 144; 1967 Nos. 67, 116 and 158; 1968 Nos. 44, 76, 88 and 146; 1969 Nos. 44, 107 and 185; 1970 Nos, 39, 94, 119 and 186; 1971 Nos. 44, 101, 136 and 154; 1972 Nos. 32, 121 and 205; 1973 Nos. 15, 57, 139 and 229; 1974 Nos. 37, 126 and 222; 1975 Nos. 50, 148 and 209; 1976 Nos. 84, 150, 195 and 255; 1977 Nos. 39, 125 and 221; 1978 Nos. 47, 142, 153 and 245; 1979 Nos. 51, 55, 144 and 250; 1980 Nos. 69, 213 and 338; 1981 Nos. 52, 212, 218 and 345; 1982 Nos. 69, 76, 179, 334 and 372.

                      

Printed by Authority by the Commonwealth Government Printer